Skip to main content
. 2023 Nov 2;39(9):600–610. doi: 10.1089/jop.2023.0056

Table 1.

Major Patient Selection Criteria

Inclusion
  • ≥18 years of age

  • Reported history of dry eye and had used or desired to use eye drops to treat the condition for ≥6 months before the first treatment visit

  • On treatment visits 1 and 2 patients had to have
    • ○ BCVA of ≥0.7 logMAR (Snellen equivalent score of ≥20/100)
    • ○ Score of ≥2 on the Ora Calibra® Ocular Discomfort and 4-Symptom Questionnaire in ≥1 of the dry eye symptoms
    • ○ Schirmer's test score of ≤10 and ≥1 mma
    • ○ Corneal fluorescein staining score of ≥2 in any corneal region (inferior, central, or superior) according to the Ora Calibra Corneal and Conjunctival Staining Scale for Grading of Fluorescein Staining in ≥1 eyea
    • ○ Conjunctival redness score ≥1 according to the Ora Calibra Conjunctival Redness for Dry Eye Scale in ≥1 eye (2-week visit pre-CAE)a
  • Demonstrated response to CAE at baseline and 2-week visit in the same eye(s)a
    • ○ ≥1 point increase in fluorescein staining in the inferior region in ≥1 eye after CAE exposure
    • ○ Ocular Discomfort score ≥3 at ≥2 time points in ≥1 eye during CAE exposure

Exclusion
  • Clinically significant slit-lamp findings at screening, including active blepharitis, meibomian gland dysfunction, lid margin inflammation, or active ocular allergies that required therapeutic treatment or would interfere with study

  • Been diagnosed with an ongoing ocular infection or active ocular inflammation

  • Worn contact lenses within 7 days of screening or planned to wear

  • LASIK surgery performed within 12 months, ocular and/or lid surgeries in past 6 months or planned during the study

  • Laser procedures in the previous 3 months

  • Use of cyclosporine or lifitegrast ophthalmic solutions within 60 days of screening

  • Use of or anticipated use of temporary punctal plugs during study that were not stable within 30 days of screening

  • Unable to discontinue topical ophthalmic prescriptions for the duration of the trial

a

At least 1 eye (same eye) had to satisfy all these criteria.

BCVA, best-corrected visual acuity; CAE, controlled adverse environment; logMAR, logarithm of the minimum angle of resolution.